Clinical trials
Apatinib clinical trials
Below are recruiting apatinib clinical trials, each written for real people, not researchers. We’re tracking 83 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06831175RecruitingPhase 2
PD-1 inhibitor combined with apatinib and mitotane for advanced adrenal cancer
This trial tests a new combination of drugs (PD-1 inhibitor, apatinib, and mitotane) for people with advanced adrenal cortical carcinoma that cannot be removed by surgery. The goal is to see if this combination is safe and effective for those who have not yet received standard first-line treatment.
Chengdu, SichuanAges 18–70 - NCT06889688RecruitingPhase 3
New drug combo vs. chemo for advanced triple-negative breast cancer
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
Guangzhou, GuangdongAges 18–70 - NCT06925243RecruitingPhase 3
Apatinib, Sintilimab, and Chemo for Intestinal Gastric Cancer
This phase 3 trial tests adding the targeted drug apatinib to a standard combination of sintilimab (immunotherapy) and chemotherapy (SOX regimen) given before surgery for a specific type of stomach or gastroesophageal junction cancer (intestinal type, HER2-negative). The goal is to see if the three-drug combination works better than the two-drug combination in shrinking the tumor and improving outcomes before surgery.
Lanzhou, GansuAges 18–75 - NCT06925516RecruitingPhase 2
Apatinib plus immunotherapy and chemo for unresectable bile duct cancer
This study tests a combination of two drugs (apatinib and adebrelimab) with standard chemotherapy for people with bile duct cancer that cannot be removed surgically. The goal is to see if this combination works better than chemotherapy alone.
Guangzhou, GuangdongAges 18–75 - NCT07026149RecruitingPhase 2
Combination therapy before surgery for stomach cancer
This trial tests a combination of radiation, chemotherapy (SOX), and two targeted drugs (apatinib and camrelizumab) before and after surgery for stomach or gastroesophageal junction cancer. It aims to see if this approach is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07033819RecruitingPhase 2
Fuzuloparib and apatinib before surgery for ovarian cancer
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
Beijing, Beijing MunicipalityAges 18–70 - NCT07135544RecruitingPhase 2
Adebrelimab plus apatinib and chemo for new bile duct cancer
This study tests a combination of three medicines (adebrelimab, apatinib, and standard chemotherapy) for people with newly diagnosed bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if the combination can shrink the tumor and make it possible to remove later.
Wuhan, HubeiAges 18–80 - NCT07479732RecruitingPhase 1/Phase 2
Apatinib with chemo for advanced osteosarcoma
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
BeijingAges 12–65 - NCT07569679RecruitingPhase 2
Combination Chemotherapy and Immunotherapy for Biliary Tract Cancer
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
Xi'an, ShaanxiAges 18 years+ - NCT06773156Enrolling by invitationPhase 2
Adebrelimab plus apatinib after chemoradiation for limited-stage SCLC
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
Nanchang, JiangxiAges 18–75 - NCT06482086RecruitingPhase 2
Using tumor models to guide drug choice for advanced thyroid cancer
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
Chengdu, SichuanAges 18 years+ - NCT05934331RecruitingPhase 2
Study for CLDN18.2-positive advanced gut cancers after first treatment
This Phase 2 trial tests a combination anti-cancer medicine (LM-302) plus other anti-tumor treatments for advanced gastrointestinal cancers. It’s designed for people whose tumors test positive for CLDN18.2 and who have already tried standard first-line treatment but didn’t respond or couldn’t tolerate it.
ShanghaiAges 18–80 - NCT07289997RecruitingPhase 2
Combination therapy for advanced AFP-producing gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
Shijiazhuang, HebeiAges 18 years+ - NCT07334483RecruitingPhase 2
Radiation plus targeted immunotherapy for liver cancer
This trial tests a combination of radioactive microspheres (Yttrium-90) with targeted immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer (HCC) that cannot be surgically removed. It may be an option for those with intermediate-stage disease who haven't had prior systemic therapy.
BeijingAges 18–75 - NCT04072042RecruitingPhase 2
Test a VEGFR2 drug for sarcoma with lung lesions
This Phase 2 study tests a VEGFR2-targeted medicine in people with advanced or metastatic sarcoma whose cancer cannot be fully removed by surgery. It focuses on participants who have lung (pulmonary) lesions and whose prior standard chemotherapy did not work, to see if the biomarker-driven approach can improve outcomes.
Shanghai, Shanghai MunicipalityAges 8–65 - NCT04318730RecruitingPhase 2
Study of immunotherapy plus targeted drug for adrenal cancer
This trial tests whether combining camrelizumab (an immune treatment) with apatinib (a targeted drug) can shrink recurrent or metastatic adrenal cancer after standard treatment didn’t work. It may help some people control tumor growth when other treatments have already been tried.
Chengdu, SichuanAges 18 years+ - NCT04803539RecruitingPhase 2/Phase 3
ctDNA-guided booster treatment after chemo for triple-negative breast cancer
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
Guandong, GuangdongAges 18–80 - NCT05069857RecruitingPhase 2
New pre-surgery treatment tailored to cancer markers in mouth cancer
This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05192798RecruitingPhase 2
Albumin-bound chemo plus anti-blood-vessel drugs for TNBC
This Phase 2 study tests a chemotherapy called albumin-bound paclitaxel combined with medicines that block new blood vessel growth (antiangiogenic agents) for women with recurrent or metastatic triple-negative breast cancer. It aims to see whether this combination can better control cancer when it comes back or has spread.
Bengbu, AnhuiAges 18–80 - NCT05409482Recruiting
Areal-world test of camrelizumab plus apatinib for liver cancer
This study looks at how well a combination of camrelizumab and apatinib works for people with unresectable hepatocellular carcinoma (liver cancer you can’t remove with surgery). It is designed to see results in real-life care for patients who have limited options after standard treatment.
Fuzhou, FujianAges 18–75 - NCT05582499RecruitingPhase 2
Neoadjuvant treatment study for certain breast cancers
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05594095RecruitingPhase 2
Study for advanced ER+ HER2− breast cancer after CDK4/6 therapy
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05713994Recruiting
Liver cancer treatments together for unresectable liver tumors
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
Quanzhou, FujianAges 18 years+ - NCT05717738Recruiting
Immunotherapy plus targeted drugs after TACE for liver cancer
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
Quanzhou, FujianAges 18 years+
Hear when a new Apatinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for apatinib?
- Yes. Clin2 currently lists 83 recruiting apatinib studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a apatinib trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a apatinib trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.